inflammatory biomarkers as predictors of car-t efficacy in multiple myeloma
Published 6 months ago • 99 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
0:48
selecting patients with multiple myeloma for car-t therapy
-
0:59
phase i study of cart-ddbcma in r/r multiple myeloma
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
1:46
car-t therapy vs bites in multiple myeloma: current outlooks & the importance of patient selection
-
5:34
a blood-based prognostic biomarker in inflammatory bowel disease
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
3:48
abecma car t-cell therapy for multiple myeloma
-
1:57
disparities in access to car-t and bsab therapy for multiple myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:01
ctcs as a biomarker of tumor burden in multiple myeloma
-
1:24
predictive biomarkers of response to venbd in r/r mm
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
3:59
bispecific t-cell engagers in the treatment of myeloma
-
0:41
mechanism of action of the tri-specific t-cell activating construct hpn217 in r/r multiple myeloma
-
2:30
using biomarkers to identify molecular lesions and monitor response to treatment in multiple myeloma
-
2:17
mrd: a promising biomarker in multiple myeloma
-
3:44
clinical advances with car-ts and bispecifics in r/r myeloma
-
1:53
the future of multiple myeloma treatment
-
2:40
recent advances in car-t therapy for mds
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma